Supportive care in hematologic malignancies

Current Opinion in Hematology

Volumn 5, Issue 4, 1998, Pages 271-286

  Fetscher, Sebastian ^a   Mertelsmann, Roland ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; THROMBOPOIETIN;

CELL PROTECTION; DEEP VEIN THROMBOSIS; DEMETHYLATION; DRUG HYPERSENSITIVITY; FLUSHING; GRANULOCYTE; HICCUP; HUMAN; HYPOCALCEMIA; HYPOTENSION; INFECTIOUS COMPLICATION; LEUKEMIA; LUNG EMBOLISM; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SOMNOLENCE; TRANSFUSION; VOMITING;

EID: 0032443080     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199807000-00007     Document Type: Review

References (91)

1. Spyridonidis A, Mertelsmann R, Henschler R: Hematopoietic cell proliferation and differentiation: Curr Opin Hematol 1996, 3:321-328.
2. Fetscher S, Mertelsmann R: Supportive care in hematological malignancies: hematopoietic growth factors, transfusions, infectious complications. Curr Opin Hematol 1997, 4:248-255.
3. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practise guidelines. J Clin Oncol 1994, 12:2471-2508.
4. Update of American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practise guidelines. J Clin Oncol 1996, 14:1957-1960.
5. Kaushansky K: Thrombopoietin: understanding and manipulating platelet • production. Ann Rev Med 1997, 48:1-11. Valuable overview and lucid discussion of expected and unexpected findings in current clinical studies on TPO.
6. Fanucci M, Glaspy J, Crawford J. Garst J, Figlin R, Sheridan W, et al.: Effects of polyethylen glycol-conjugated human megakaryocyte growth and development factor on platelet counts of patients after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409.
7. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL: Circulating thrombopoietin levels in thrombocytopenic patients, including cancer patients, following chemotherapy with or without peripheral blood progenitor cell transplantation. Br J Hematol 1996, 95:535-541.
8. Shimazaki C, Inaba T, Uchiyama H, Sumikuma T, Kikuta T, Hirai H, Ashishara E, Goto H, et al.: Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997, 19:771-775.
9. Rasko JEJ, Basser RL, Boyd J, Mansfield R, O'Malley CJ, Hussein S, et al.: Multilineage mobilization of peripheral blood progenitor cells following administration of PEG-rHuMDGF. Br J Hematol 1997, 97:871-880.
10. Ulich TR, Whitcomb L, Tang W, O'Conner-Tressel P, Tarpley J, Yi EY: Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Cancer Res 1997, 57:472-475.
11. Yi EY, Williams ST, Lee H, Malicki DM, Chin EM, Yin S, et al.: Keratinocyte growth factor ameliorates radiation and bleomycin-induced lung injury and mortality. Am J Pathol 1996, 149:1963-1970.
12. Bansal GS, Cox HC, Gomm JJ, Yiangou C, Coombes RC, Johnston CL: Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer 1997, 75:1567-1574.
13. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of myeloid leukemia. Blood 1996, 88:3675-3685.
14. Johnson PRE, Liu Yin JA: The role of granulocyte- and granulocyte-• macrophage-colony stimulating factors in the treatment of acute myeloid leukemia. Br J Haematol 1997, 97:1-8. A thorough and concise summary of the role of GM-CSF and G-CSF in AML from a British perspective.
15. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 1997, 11:328-331.
16. Bächner T, Hiddemann W, Wörmann B, Zühlsdorf M, Rottmann R, Innig G, et al.: Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 1997, 24:124-129.
17. Terpstra W, Löwenberg B: Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997, 11:315-319.
18. Metcalf D: The Charlotte Friend Memorial Lecture. The role of hematopoi•• etic growth factors in the development and suppression of myeloid leukemias. Leukemia 1997, 11:1599-1604. Succinct and lucid analysis of our current understanding of the biology of HGF in myeloid leukemias.
19. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JAL, Papa G, et al.: A random• ized, double-blind, placebo-controlled phase III study of filgrastim in remission induction and consolidation chemotherapy for adults with de novo acute myeloid leukemia. Blood 1997, 89:4710-4718. 521-patient study suggesting relatively impressive benefits of G-CSF with regards to neutrophil recovery and infectious morbidity.
20. Löwenberg B, Boogaerts MA, Daenen SMGJ, et al.: Value of different modalities of granulocyte-colony stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997, 15:3496-3506. 253-patient study showing no benefits of priming and no reduction in infectious morbidity with GM-CSF.
21. Moore JO, Dodge RK, Amrem PC, Kolitz J, Lee EJ, Powell B, Godfrey S, et al.: Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantranone: Cancer and Leukemia Group B Study 9022. Blood 1997, 89:780-788.
22. Karp JE: Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias. Curr Opin Oncol 1998, 10:3-9.
23. Zühlsdorf M, Wörmann B, Hiddemann W, Büchner T: G-CSF before, during, and after multiple course chemotherapy of secondary AML: a randomized study. Blood 1997, 98(Suppl 1):749a.
24. Ohno R, Miyawaki S, Hatake K, et al.: Human urinary macrophage-colony stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 1997, 15:2954-2965.
25. Kaddar A, Edinger M, Wirth K, Schaefer HE, Lübbert M, Lindemann A: Increased numbers of bone marrow blasts in acute myeloid leukemia treated with G-CSF after chemotherapy. Br J Haematol 1997, 98:492-493.
26. Adkins DR, Brown RA, DiPersio JF: Granulocyte-colony stimulating factor with induction treatment of acute myelogenous leukemia [Letter]. J Clin Oncol 1997, 15:862-863.
27. Zittoun R, Cadiou M: Granulocyte-colony stimulating factor with induction treatment of acute myelogenous leukemia [reply]. J Clin Oncol 1997, 15:863.
28. O'Brien SO, Kantarjian H, Beran M, Koller C, Talpaz M, Lerne S, Keating MJ: Fludarabine and granulocyte colony-stimulating factor in patients with chronic lymphocytic leukemia. Leukemia 1997, 11:1631-1635.
29. Corcione A, Corrias MV, Daniele S, Zupo S, Pistoia V: Expression of granulocyte colony-stimulating factor and granulocyte colony-stimulating factor receptor genes in partially overlapping monoclonal B-cell populations from chronic lymphocytic lymphoma patients. Blood 1996, 87:2681-2689.
30. Carapeti M, Soede-Bobok A, Hochhaus A, Sill H, Trow IP, Goldman JM, Cross NCP: Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia. Leukemia 1997, 11:1005-1008.
31. Matshushita K, Arima N, Ohtsubo H, Fujiwara H, Hidaka S, Kukita T, et al.: Granulocyte-colony stimulating factor-induced proliferation of adult T-cell leukaemia cells. Br J Haematol 1997, 96:715-723.
32. Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, et al.: Prospective randomized placebo-controlled study of granulocyte colony-stimulating factor without autologous stem-cell transplantation after highdose melphalan in patients with multiple myeloma. J Clin Oncol 1997, 15:660-666.
33. Stahel RA, Jost L, Honegger H, Betts E, Goebel MEM, Nagler A: Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997, 15:1730-1735.
34. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, et al.: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphomas. Blood 1997, 11:3974-3979.
35. Caprizzi RL: The preclinical basis for broad-spectrum cytoprotection of normal tissues from cytotoxic therapies by Amifostine (Ethyol). European Journal of Cancer 1996, 32A(supplement 4):S5-S16.
36. Alberts DS, Speicher LA, Krutzsch M, Wymer J, Caprizzi RL, Conlon L, Barrett A, Aickin M: WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anti-cancer drugs against human ovarian and breast cancer cells. Eur J Cancer 1996, 32A(Suppl 4):S17-S20.
37. Bukowski RM: Amifostine (Ethyol): dosing, administration and patient management guidelines. Eur J Cancer 1996, 32A(Suppl 4):S46-S49.
38. Schuchter LM: Evaluation of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Eur J Cancer 1996, 32A(Suppl 4):S40-S42.
39. Gorin NC: The potential role of amifostine (Ethyol) in hematological malignancies. Eur J Cancer 1996, 32A(Suppl 4):S31-S39.
40. Shpall EJ, Stemmer SM, Hami L, et al.: Amifostine (WR-2721 ) shortens the engraftment period after 4-hydroperoxy-cyclophosphamide-purged bone marrow in breast cancer patients receiving high dose chemotherapy with autologous bone marrow support. Blood 1994, 83:3131-3137.
41. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R: Stimulation of hematopoiesis in patients with myelodysplastic syndrome. Blood 1997, 90:3364-3369.
42. Karp JE: Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias. Curr Opin Oncol 1998, 10:3-9.
43. Stasi R, Brunetti M, Bussa S, Conforti M, DiGiulio C, Crescenzi A, Terzoli E, Vecchione A, Pagano A: Response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Cancer Res 1997, 3:733-739.
44. Momparler RL, Cote S, Eliopoulos N: Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 1997, 11(Suppl 1):S1-6.
45. Momparler RL, Cote S, Eliopoulos N: Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (decitabine) for the therapy of leukemia. Leukemia 1997, 11:175-180.
46. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, et al.: Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997, 11:1617-1620.
47. Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M: Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 1997, 11(Suppl 1):S35-36.
48. Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H: Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 1997, 11 (Suppl 1):S32-34.
49. Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, Di Leone L, Loitzembauer B, Kalakun L: Decitabine (DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 1997, 11 (Suppl 1):S28-31.
50. Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, et al.: A randomized phase II study on the effects of 5-Aza-2′ -deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997, 11(Suppl 1):S24-27.
51. Wijermans PW, Krulder JW, Huijgens PC, Neve P: Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997, 11(Suppl 1):S19-23.
52. Wijermans PW, Krulder JW, Huijgens PC, Neve P: Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997, 11:1-5.
53. Hughes WT, Armstrong D, Bodey GP, et al.: 1997 Guidelines for the use •• of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997, 25:551-573. Number one referral for the management of infections in hematology and oncology. An extensive update and revision of the 1990 report by the Infectious Diseases Society of America, it should be thoroughly studied by anyone deciding on the antimicrobial therapy of neutropenic patients.
54. Maschmeyer G, Hiddemann W, Link H, Cornely OA, Buchheidt D, Glaß B. • Adam D: Management of infections during intensive treatment of hematologic malignancies. Ann Hematol 1997, 75:9-16. Excellent and concise reference for the management of infections during and after myelotoxic therapy of hematological disorders from a European perspective.
55. Uzun A, Anaissie EJ: Antifungal prophylaxis in patients with hematological malignancies: a reappraisal. Blood 1995, 86:2063-2072.
56. DeShazo RD, Chapin K, Swain RE: Fungal sinusitis. N Engl J Med 1997, • 337:254-259. Excellent presentation of an important and frequently underestimated problem.
57. Fisher EW, Toma A, Pisher PH, Cheemann AD: Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otology 1991, 105:575-577.
58. Mahlknecht U, Lintig FV, Mertelsmann R, Lindemann A, Luebbert M: Successful treatment of disseminated central nervous system aspergillosis in a patient with myeloblastic leukemia. Leuk Lymphoma 1997, 27:191-194.
59. Schwartz S, Milatovic D, Thiel E: Successful treatment of cerebral aspergillosis with a novel triazole (Voriconazole) in a patient with acute leukaemia. Br J Hematol 1997, 97:663-665.
60. Khoury H, Adkins D, Miller G. Goodnough L, Brown R, DiPersio J: Resolution of central nervous system aspergillosis in a transplant recipient. Bone Marrow Transplant 1997, 20:179-180.
61. Heinemann V, Bosse D, Jehn U, et al.: Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 1997, 1275-1280.
62. Mehta J, Kelsey S, Chu P, Powles R, Hazel D, Riley U, Evans C, Newland A, Treleaven J, Singhal S: Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematological malignancies. Bone Marrow Transplant 1997,20:39-43.
63. Prentice HG, Hann IM, Herbrecht R, et al.: A randomized comparison of liposomal versus conventional therapy for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Hematol 1997, 98:711-718.
64. Zernikow B, Fleischhack G, Hasan C, Bode U: The occurrence of cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B. Mycoses 1997, 40:359-361.
65. Toren A, Or R, Ackerslein A, Nagler A: Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation. Bone Marrow Transplant 1997, 20:67-69.
66. Edwards JE, et al.: International conference for the development of a •• consensus on the management and prevention of severe candidat infections. Clin Infect Dis 1997, 25:43-59. Comprehensive assessment of the diagnosis, prophylaxis, and therapy of candidiasis. Excellent reference for virtually all major clinical decisions in candidal disease.
67. Boutati El, Anaissie EJ: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
68. Cesaro S, Petris MG, Rosetti F, Cusinato R, Pipan C, Guido M, et al.: Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood 1997, 90:1315-1320.
69. Tada K, Tajiri H, Kozaiwa K, Sawada A, Guo W, Okada S: Role of screening for hepatitis C in children with malignant disease and who undergo bone marrow transplantation. Transfusion 1997, 37:641-644.
70. Ekert H, Ekert NL, Street AM, et al.: Haemophilia A management in Victorian, New South Wales and South Australia Haemophilia centers. Med J Australia 1995, 162:569-571.
71. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al.: long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992, 327:1906-1911.
72. Ribas A, Gale RP: Should people with hepatitis C virus infection receive a • bone marrow transplant. Bone Marrow Transplant 1997, 19:97-99. Concise, decisive, and reassuring recommendations for clinicians considering HCV-positive patients for bone marrow transplantation.
73. Alter MJ, Gallagher M, Morris T: Acute Non-A-e hepatitis in the USA and the role of hepatitis G virus infection. N Engl J Med 1997, 336:741 -746.
74. Alter MJ, Nakatsuj Y, Melpolde J, et al.: The incidence of transfusion-associated hepatitis G virus infection an its relation to liver disease. N Engl J Med 1997, 336:747-754.
75. Corbi C, Traineau R, Esperou H, Ravera N, Portelette E, Benbuan M, et al.: Prevalence and clinical feature of hepatitis G virus infection in bone marrow allograft recipients. Bone Marrow Transplantation 1997, 20:965-968.
76. Bergmann OJ, Mogensesn SC, Ellermann-Eriksen S, Ellegaard J: Acyclovir prophylaxis and fever during remission induction therapy of patients with acute myeloid leukemia: a randomized, double-blind placebo-controlled trial. J Clin Oncol 1997, 15:2269-2274.
77. Kingreen D, Nitsche A, Beyer J, Siegert W: Herpes simplex infection of the jejunum occurring in the early post-transplantation period. Bone Marrow Transplant 1997, 20:989-991.
78. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, et al.: Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Intern Med 1997, 127:267-273.
79. Maki DG, Stolz SM, Wheeler S, Mermel LA: Prevention of central venous catheter-related bloodstream infection by use of an antispetic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997, 127:257-266.
80. Logghe C, Van Ossel Ch, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ: Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infections in leukaemic patients: a randomized controlled trial. J Hosp Infect 1997, 37:145-156.
81. Raad I: Vascular catheters impregnated with antimicrobial agents: present knowledge and future direction. Infect Control Hosp Epidemiol 1997, 18:227-229.
82. Klein HG, Strauss RG, Schiffer CA: Granulocyte transfusion therapy. Semin Hematol 1996, 33:359-368.
83. Klein HG, Price TH, Strauss RG, Stroncek D: Granulocyle transfusion redux. American Society of Hematology Annual Meeting Educational Book 1997, 138-145.
84. Dignani MC, Anaissie EJ, Hester JP, O'Bried S, Vartivian SE, Rex JH, et al.: Treatment of neutropenia-related fungal infections with granulocyte-colony stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11:1621-1630.
85. Adkins D, Goodgold H, Hendershott L, Johnston M, Cravens D, Spitzer G: Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1997, 19:809-812.
86. Stroncek DF, Clay ME, Herr G, Smith J, llstrup S, McCullough J: Blood counts in healthy donors 1 year after the collection of granulocyte-colony stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997, 37:304-308.
87. AuBuchon JP, Birkmeyer JD, Busch MP: Safety of the blood supply in the • United States: opportunities and controversies. Ann Intern Med 1997, 127:904-909. Excellent discussion of modern transfusion medicine in the era of near-perfection.
88. Wagner S: Transfusion-related bacterial sepsis. Curr Opin Hematol 1997, 4:464-469. Thorough review of the topic; contains an up-to date discussion of the role of bacterial contamination in hematopoietic progenitor preparations.
89. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP: Randomized study of prophylactic platelet transfusions threshold during induction therapy for adult acute leukemia: 10.000/μl versus 20.000/μl. J Clin Oncol 1997, 15:11 43-1149.
90. Bernstein SH, Nademanee AP, Vose JM, et al.: A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998, 91 (9):3509-3517.
91. 9 trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998, 91(10):in press.